Takeda Pharmaceutical announced it has entered into an agreement to sell its majority shareholding of 51.34% in Guangdong Techpool Bio-Pharma Co. The shareholding is to be acquired in an all-cash, combined Stock Purchase Agreement by Takeda’s joint venture partner in Techpool: Shanghai Pharmaceutical Holding Co. Ltd. and a fund managed by SFund International Investment Fund Management Limited, a wholly-owned subsidiary of Guangzhou Industrial Investment Fund Management Co.The agreement remains subject to approval from the State Administration for Market Regulation in the People’s Republic of China. The Base Payment for the purchase price of Takeda’s shareholding is $280M. Upon completion of the transaction, the Fund will purchase approximately 49% of the Takeda shareholding, and Shanghai Pharma will acquire approximately 51% of it.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.